miR-195 Has a Potential to Treat Ischemic and Hemorrhagic Stroke through Neurovascular Protection and Neurogenesis

Tissue plasminogen activator is the only U.S. FDA-approved therapy for ischemic stroke, while there is no specific medication for hemorrhagic stroke. Therefore, the treatment of acute stroke continues to be a major unmet clinical need. We explored the effects of miR-195 on neurovascular protection a...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Hsin-Yun, Wang, Yung-Song, Hsu, Po-Yuan, Chen, Chien-Yuan, Liao, Yi-Chu, Juo, Suh-Hang H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6365409/
https://www.ncbi.nlm.nih.gov/pubmed/30775405
http://dx.doi.org/10.1016/j.omtm.2018.11.011

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6365409/
https://www.ncbi.nlm.nih.gov/pubmed/30775405
http://dx.doi.org/10.1016/j.omtm.2018.11.011

Ejemplares similares